Alnylam Pharmaceuticals, Inc. (ALNY)

Check out top investors' recommendation for ALNY
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
115.18
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
92%/8%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company’s early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington’s disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Alan Carr Needham & Company Buy   Nov 03, '17     152.00  Nov 03, '18  N/A 
Edward Tenthoff Piper Jaffray Buy   Nov 02, '17     188.00  Nov 02, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Nov 02, '17     151.00  Nov 02, '18  N/A 
Terence Flynn Goldman Sachs Buy   Oct 02, '17       Oct 02, '18  N/A 
Michael Yee RBC Capital Markets Buy   Sep 25, '17     102.00  Sep 25, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Sep 21, '17     123.00  Sep 21, '18  N/A 
Christopher Marai Wedbush Securities Inc. Sell   Sep 15, '17     56.00  Sep 15, '18  N/A 
Geoff Meacham JPMorgan Buy   Sep 07, '17     105.00  Sep 07, '18  N/A 
Alan Carr Needham & Company Buy   Sep 07, '17     85.00  Sep 07, '18  N/A 
Edward Tenthoff Piper Jaffray Buy   Sep 07, '17     110.00  Sep 07, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Sep 07, '17     93.00  Sep 07, '18  N/A 
Eun Yang Jefferies & Co. Buy   Aug 24, '17     102.00  Aug 24, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Aug 10, '17     96.00  Aug 10, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Aug 04, '17     100.00  Aug 04, '18  N/A 
Alethia Young Deutsche Bank Securities Buy   Jun 27, '17     96.00  Jun 27, '18  N/A 
Ritu Baral Canaccord Genuity Buy   Jun 26, '17     100.00  Jun 26, '18  N/A 
Alan Carr Needham & Company Buy   Jun 26, '17     98.00  Jun 26, '18  N/A 
Alan Carr Needham & Company Buy   May 16, '17     68.00  May 16, '18  N/A 
Ritu Baral Canaccord Genuity Buy   May 15, '17     100.00  May 15, '18  N/A 
Edward Tenthoff Piper Jaffray Buy   May 15, '17     118.00  May 15, '18  N/A 
< previous1234